Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.97) by $0.57, Briefing.com reports. The firm had revenue of $319.29 million for the quarter, compared to the consensus estimate of $312.53 million. Alnylam Pharmaceuticals had a negative […]
Parametrica Management Ltd cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 31.4% during the fourth quarter, HoldingsChannel reports. The fund owned 9,500 shares of the biopharmaceutical company’s stock after selling 4,339 shares during the quarter. Alnylam Pharmaceuticals comprises approximately 4.6% of Parametrica Management Ltd’s holdings, making the stock its 8th biggest […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) CEO Yvonne Greenstreet sold 7,615 shares of the stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $1,481,802.85. Following the transaction, the chief executive officer now directly owns 30,332 shares in the company, valued […]
Sumitomo Mitsui Financial Group began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) in a research report sent to investors on Wednesday, Marketbeat reports. The brokerage issued a neutral rating and a $220.00 price objective on the biopharmaceutical company’s stock. Several other brokerages have also recently issued reports on ALNY. Morgan Stanley raised […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) President Akshay Vaishnaw sold 2,392 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $194.59, for a total transaction of $465,459.28. Following the transaction, the president now directly owns 17,890 shares in the company, […]